Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4(+)CD25(+)FOXP3(+) Regulatory T-Cells

OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal f...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Monti, Paolo, Scirpoli, Miriam, Maffi, Paola, Piemonti, Lorenzo, Secchi, Antonio, Bonifacio, Ezio, Roncarolo, Maria-Grazia, Battaglia, Manuela
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2008
Témata:
Immunology and Transplantation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518485/
https://ncbi.nlm.nih.gov/pubmed/18559659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db08-0138
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky